Temporal Clustering of Antiglomerular Basement Membrane Disease in COVID-19 Pandemic: A Case Series
Authors:
- Jegan ArunachalamJAJegan Arunachalam
- Manorajan RajendranMRManorajan Rajendran
Open Access
- 1 November 2021
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 14, 393-398
Abstract
Anti-glomerular basement membrane disease (anti-GBM) affects mainly kidneys and lungs. It requires aggressive immunosuppressive treatment. Since the emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there has been an increased number of new cases of anti-GBM disease presenting as rapidly progressive glomerulonephritis (RPGN). The causal relationship is still speculative. We report a case series of four patients affected with COVID-19 infection presenting later with anti-GBM disease.Keywords
This publication has 12 references indexed in Scilit:
- Renal Involvement and Early Prognosis in Patients with COVID-19 PneumoniaJournal of the American Society of Nephrology, 2020
- Anti-Glomerular Basement Membrane DiseaseClinical Journal of the American Society of Nephrology, 2017
- Anti-glomerular basement membrane disease: Case series from a tertiary center in North IndiaIndian Journal of Nephrology, 2017
- Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane DiseaseClinical Journal of the American Society of Nephrology, 2016
- Clustering of Anti-GBM Disease: Clues to an Environmental Trigger?Clinical Journal of the American Society of Nephrology, 2016
- Autoimmune kidney diseasesAutoimmunity Reviews, 2010
- Clinical features and outcome of patients with both ANCA and anti-GBM antibodiesKidney International, 2004
- Rapidly progressive crescentic glomerulonephritisKidney International, 2003
- The Goodpasture AutoantigenJournal of Biological Chemistry, 1999
- Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4.BMJ, 1986